Table 1.

Baseline demographics of patients (randomized and treated)

Patient characteristic	Value(s) for patients without cirrhosis treated with:						Value(s) for patients with cirrhosis treated with:
	Placebob (n = 14)	100 mg deleobuvir (n = 9)	200 mg deleobuvir (n = 9)	400 mg deleobuvir (n = 9)	800 mg deleobuvir (n = 9)	1,200 mg deleobuvir (n = 10)	400 mg deleobuvir (n = 8)	600 mg deleobuvir (n = 5)
Age (yrs, mean ± SD)	47.2 ± 9.1	50.3 ± 11.9	51.7 ± 8.5	52.3 ± 8.7	47.3 ± 12.7	46.8 ± 8.6	55.4 ± 7.0	56.2 ± 8.1
Body mass index (kg/m2, mean ± SD)	24.7 ± 2.9	26.7 ± 3.6	24.9 ± 2.8	24.5 ± 1.8	26.2 ± 3.4	23.9 ± 3.1	25.8 ± 3.8	24.6 ± 1.4
Baseline HCV RNA (mean log10 ± SD)	6.39 ± 0.77	6.14 ± 0.55	6.49 ± 0.53	6.59 ± 0.51	6.35 ± 0.68	6.47 ± 0.47	6.52 ± 0.47	6.38 ± 0.39
Sex (n)
No. of males	9	8	6	8	7	10	6	4
No. of females	5	1	3	1	2	0	2	1
Time since HCV diagnosis (yrs, mean ± SD)	10.4 ± 8.0	9.9 ± 7.2	9.0 ± 5.2	11.8 ± 7.7	8.1 ± 5.9	9.5 ± 10.0	15.3 ± 5.2	11.9 ± 7.2
No. with indicated HCV genotype (by sequencing)
Subtype 1a	8	4	3	6	2	6	2	1
Subtype 1b	6	5	6	3	7	4	6	4
No. PegIFN-RBV naive	4	1	2	3	3	2	1
Prior PegIFN-RBV response
No. whose data were missing/not assessable	2	3	1	0	0	1	3c	2
No. of nonrespondersa	3	5	3	4	1	3	3	3
No. with breakthrough	0	0	0	0	1	0	0	0
No. with relapse	5	0	3	2	4	4	2	0
Total	10	8	7	6	6	8	8	5

^aThe 19 nonresponders without cirrhosis were 6 null responders, 5 partial responders, and 8 nonresponders of unknown type. Of the 6 nonresponders with cirrhosis, there were 4 null responders, 1 partial responder, and 1 nonresponder of unknown type.

^bPatients were randomized 3:1 between active treatment and placebo; the data from all patients randomized to placebo are combined in the table.

^cIncludes the PegIFN-RBV-naive patient.